Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (August 2026)
31 slides from Century Therapeutics's investor presentation, August 2026
Slide 1: Advancing Curative Medicines Through Cell Engineering
Advancing Curative Medicines Through Cell Engineering August 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts o
Slide 3: Focused. Funded. Executing.
Century Therapeutics: Advancing Curative Medicines Through Cell Engineering Powered by The Cell Foundry and Allo-EvasionTM 5.0 Foundational Platform Tech: Well Funded: Targeting Functional Cures: Engine to create and scale T1D and Autoimmune disease Multiple Anticipated Near-Term cellular medicines
Slide 4: Prioritized pipeline progressing toward the clinic
Prioritized pipeline progressing toward the clinic Allo-Evasion engineered in all programs Product Targets Indications Research IND-enabling Clinical Priority Program CNTY-813 Islet Islet cells Type 1 diabetes (Allo-Evasion 5.0) Transplantation infusions in outpatient setting Additional Programs1 CN
Slide 5: Century executive team
Century executive team Experienced leadership with a track record of driving innovation and success in cell therapy Brent Pfeiffenberger, PharmD, MBA Chad Cowan, PhD Greg Russotti, PhD Megan Bilson Chairman and Chief Scientific Officer Chief Technology and Manufacturing Officer Chief People Officer
Slide 6: New hope for T1D patients: CNTY-813 and the clinical case for islet replacement
New hope for T1D patients: CNTY-813 and the clinical case for islet replacement iPSC-derived islet replacement therapy engineered with Allo-Evasion 5.0
Slide 7: Significant unmet need in type 1 diabetes (T1D)
Significant unmet need in type 1 diabetes (T1D) ~9 million people worldwide living with T1D1 Lifetime economic burden of T1D (US) estimated at ~$813 Billion2 T1D is associated with serious comorbidities and complications3 Despite insulin therapy, people living with T1D face a high risk of life-limit
Slide 8: Replacing lost insulin-producing islets has T1D curative potential
Replacing lost insulin-producing islets has T1D curative potential Supply and need for chronic immunosuppression limits broader use despite historical clinical validation In T1D, islet cells are destroyed Islet transplantation provides a potentially curative therapy for T1D Insulin independence achi
Slide 9: Stem-cell derived islets can restore islet function and address scalability
Stem-cell (SC) derived islets can restore islet function and address scalability Chronic immunosuppression still limits broader use Zimislecel (VX-880) is a SC-derived 10/12 patients receiving SC-derived islets were insulin producing islet cell therapy1,2 exogenous insulin free at 12 months after a
Slide 10: Century's potential solution to T1D is leveraging iPSCs + Allo-Evasion 5.0
Century’s potential solution to T1D is leveraging iPSCs + ALLO-EVASIONTM 5.0 CNTY-813: scalable, iPSC-derived islet replacement therapy engineered to eliminate the need for immunosuppression ALLO-EVASION 5.0: Evading cell-mediated and humoral responses No HLA-I IgG Cleavage Prevents recognition Redu
Slide 11: CD300a-TASR can protect Century's iPSC-derived cells from NK cell killing
CD300a-TASR can protect Century’s iPSC-derived cells from NK cell killing CD300a detects disordered CD300a-TASR mimics membrane lipids dead or dying cells CD300a consistently broadly expressed on NK cells ✓ CD300a-TASR mimics iPSC drug product N = 45 Diverse PBMC Donors dying cell signal to Dead/dyi
Slide 12: Century's IgG degrading protease protected cells from humoral immunity
Century’s IgG degrading protease (IDP) protected cells from humoral immunity Immunoglobulin degrading protease As a result, Century’s cells has been shown to Century T cells stably express IDP, an enzyme resist complement, antibody-directed killing, that cleaves IgGs below the hinge and antibody-dir
Slide 13: CNTY-813: iPSC-derived islet replacement therapy with Allo-Evasion 5.0
CNTY-813: iPSC-derived islet replacement therapy with Allo-Evasion 5.0 Uniquely positioned to potentially deliver a successful T1D cell replacement therapy Protection Against Cellular Free of Immune Glucose Control Scalable Drug Product and Humoral Immune Suppression Clearance Cadaveric Islets YES N
Slide 14: In-house manufacturing at scale: A competitive advantage built from experience
In-house manufacturing at scale: A competitive advantage built from experience Reproducible, scalable cell product from a single master cell bank to clinical supply 53,000 sq ft cGMP facility Single donor master cell banks Scalability with bioreactors Built-for-purpose facility producing and Clonal
Slide 15: CNTY-813: Islet function, immune-evasive engineering, and scalable manufacturing
In vitro and in vivo data support potential to provide functional cure without systemic immunosuppression CNTY-813: Clinical candidate selected with Century’s Allo-Evasion 5.0 Islet function, immune- to protect cells from immune rejection and disease-related evasive engineering, and autoantibodies s
Slide 16: Generation of islets with a 29-day defined process
Generation of islets with a 29-day defined process High purity and reproducible across batches Definitive Primitive Pancreatic Pancreatic Endoderm Gut Tube Progenitor I Progenitor II Endocrine β Cell iPSC Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Stage 1: Stage 4: Stage 6: Stage 6: Definitive
Slide 17: Phase 1 clinical manufacturing process established across multiple independent batches
Phase 1 clinical manufacturing process established and executed from MCB across multiple independent batches MCB Thaw iPSC Expansion Bioreactor Differentiation Cryopreserved Intermediate Post-Thaw Maturation Final Fresh Product • 3 Batches Consistent final product flow • 11 Samples cytometry profile
Slide 18: CNTY-813 islets contain defined, terminally differentiated endocrine cell populations
CNTY-813 islets contain defined, terminally differentiated endocrine cell populations scRNAseq Cell Type Annotations scRNAseq Cell Cycle Annotations Diff. Stage: iPSC 1 2 3 4 5 6 Population (30,151 total) Frequency β cells 66.3% FEV+ Islet Cells 26.4% ⍺ cells 5.5% δ cells 0.8% Exocrine/Ductal 1.0% •
Slide 19: CNTY-813 islet cells demonstrate robust glucose-responsive function
CNTY-813 islet cells demonstrate robust glucose-responsive function Nonclinical Potency Glucose Stimulated Insulin Secretion Stimulation Index Total Insulin Content 15 Index (20mM glucose/ 2mM glucose) Stimulation Index Glucose Stimualtion 2mM Glucose 40000 10 uIU Insulin/ 1E6 Cells 20mM Glucose 300
Slide 20: CNTY-813 islets rapidly restored normoglycemia in STZ-induced diabetic mice
CNTY-813 islets rapidly restored normoglycemia in STZ-induced diabetic mice Preclinical Potency Non-Fasted Blood Glucose Glucose Tolerance Test Normoglycemic Control Diabetic Control 600 600 No Treatment Unedited CNTY Islet Cells Blood Glucose (mg/dL) 500 Unedited CNTY Islet Cells (5M) 500 (5M) Bloo
Slide 21: CNTY-813 grafts maintain endocrine identity with no evidence of tumorigenesis in mouse models
CNTY-813 grafts maintain endocrine identity with no evidence of tumorigenesis in mouse models Endocrine graft identity over time 2 weeks 4 weeks 8 weeks 24 weeks INS+ (green) CHGA+ (orange) Merged (yellow) ✓ Endocrine graft morphology maintained Ki67+ (pink) DAPI (blue) ✓ No Ki67 increase or cyst fo
Slide 22: Allo-Evasion 5.0 protected CNTY-813 from rejection in a humanized mouse model
Allo-EvasionTM 5.0 protected CNTY-813 from rejection in a humanized mouse model Glucose Stimulation Index Glucose Tolerance Test (GTT) (11 weeks post-islet infusion) (C-peptide induction over baseline) 15 600 Glucose-Stimulated Insulin Unedited Islets Blood Glucose (mg/dL) Unedited Islets Secretion
Slide 23: CAR-iT Franchise: CD4+/CD8+ αβ CAR-iT-cell with Allo-Evasion 5.0
CAR-iT Franchise: CD4+/CD8+ αβ CAR-iT-cell with Allo-Evasion 5.0
Slide 24: Potential to address significant unmet need in autoimmunity with allogeneic CAR iT cells
CNTY-308 is a CAR-iT targeting CD19 that aims to pair the characteristics of autologous CAR-T with the convenience of an allogeneic CAR-T for the treatment of autoimmune disease Potential to address CNTY-308 (CD19 CAR iT with Allo-EvasionTM 5.0) significant unmet need • CNTY-308 expected to enter cl
Slide 25: CNTY-308 is an iPSC-derived CD19-targeted CAR-iT intended for B-cell-mediated disease
CNTY-308 is an iPSC-derived CD19-targeted CAR-iT intended for B-cell-mediated disease CNTY-308 CD4+/CD8+ αβ iT-cell • CD19-targeted CAR to target B-cells for cytotoxic depletion – 4-1BB and CD3z co-stim domain to stimulate expansion on target engagement • Displays characteristics of autologous CAR-T
Slide 26: In preclinical studies, CNTY-308 cells are comparable to primary CAR-T cells
In preclinical studies, CNTY-308 cells are ≈ comparable to primary CAR-T cells Function 1’ CAR-T CNTY-308 IL-2 secretion (pg/mL) ~3,000 ≈ ~2,000 Requires exogenous IL-2/IL-15 No ≈ No Repeat killing (rounds) >10 ≈ >10 Persistence in blood (days) 32 ≈ 32 Tumor control after rechallenge (in vivo) Yes ≈
Slide 27: Century iPSC-CAR-T cells controlled tumors, persisted for ≥1 month, and retained cytotoxic capacity
In preclinical animal studies, Century iPSC-CAR-T cells controlled tumors, persisted for ≥1 month, and retained cytotoxic capacity upon rechallenge In vivo experimental details Complete tumor control • Disseminated Nalm6 model (1e5 cells infused) Group 1: PBS only Group 2: 1' CAR−T Group 3: iPS−CAR−
Slide 28: CNTY-308 robustly depleted B cells in vitro and in vivo
CNTY-308 robustly depleted B cells in vitro and in vivo In Vitro B Cell Depletion B Cell Depletion in Human PBMC Engrafted Mice 100 Spleen Bone Marrow ✱✱✱✱ ✱✱ 40 10 Naive (MHCI+,CD3-, CD19+, Blin+cells) ✱✱✱✱ ✱✱✱ 80 ✱✱ ✱✱ Percent Killing of B Cells (%) CD20+ Cells/100um2 Femur PBMC Alone CD20+ Cells/
Slide 29: Corporate Summary
Corporate Summary
Slide 30: Focused. Funded. Executing.
Century Therapeutics: Advancing Curative Medicines Through Cell Engineering Powered by The Cell Foundry and Allo-EvasionTM 5.0 Foundational Platform Tech: Well Funded: Targeting Functional Cures: Engine to create and scale T1D and Autoimmune disease Multiple Anticipated Near-Term cellular medicines
Slide 31: www.centurytx.com
www.centurytx.com
Century Therapeutics — Investor Presentation (August 2026) on 6ix